Telix and Regeneron Announce Strategic Collaboration to Develop Next-Generation Radiopharmaceuticals

NewTimeSpace News: On April 13, 2026, Telix announced that it has entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies.

According to the agreement, the two parties will adopt a 50/50 cost and profit-sharing model. Telix will receive a US$40 million upfront payment for four initial therapeutic programs, with Regeneron having the option to expand to include four additional programs. The parties also plan to jointly develop diagnostic products, with Telix leading commercialization.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.